{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:00:55Z","timestamp":1791525655802,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000805","name":"European Centre for Disease Prevention and Control","doi-asserted-by":"publisher","award":["ECDC\/2013\/015"],"award-info":[{"award-number":["ECDC\/2013\/015"]}],"id":[{"id":"10.13039\/501100000805","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) antimicrobial resistance (AMR) data are used to inform gonorrhoea treatment guidelines; therefore the data need to be robust and representative. We assessed the extent to which Euro-GASP reflects national measures of the AMR situation for <jats:italic>Neisseria gonorrhoeae<\/jats:italic> across the European Union\/European Economic Area (EU\/EEA).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We compared data from Euro-GASP with published national gonococcal AMR data from 15 countries for azithromycin, cefixime and ciprofloxacin for the period 2009 to 2013 and performed Poisson regression to identify differences (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) between the proportions of resistant isolates. The 2014 Euro-GASP AMR data for each country (<jats:italic>n<\/jats:italic>\u2009=\u200919) were weighted to account for differences in the distribution of patient characteristics between Euro-GASP and EU\/EEA epidemiological gonorrhoea surveillance data. Data were compared to determine whether estimates of resistance levels differed with regards to the 5% threshold used to assess the clinical utility of first-line gonorrhoea treatments. We assessed the quality of decentralised testing by comparing AMR data for isolates tested both centrally and in the participating laboratories, and by evaluating external quality assessment (EQA) performance.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>There was no significant difference for azithromycin, cefixime and ciprofloxacin resistance when Euro-GASP country data were compared with data from national reports. Weighting slightly altered the Euro-GASP AMR estimates (by between \u2212\u20094.7 and 4.7% from the unweighted estimates). Weighting resulted in greater changes in estimates of resistance to azithromycin (from \u2212\u20099.5 to 2.7%) and ciprofloxacin (from \u2212\u200914.8 to 17.9%) in countries with low isolate numbers and low completeness of reporting (<jats:italic>n<\/jats:italic>\u2009=\u20093). Weighting caused AMR levels to fall below or above the 5% threshold for cefixime or azithromycin, respectively in only two countries. Susceptibility category data submitted from the decentralised Euro-GASP laboratories were concordant with the Euro-GASP data (&gt;\u200990%). EQA performance was also good; &lt;\u20095% of the minimum inhibitory concentration (MIC) results differed by &gt;\u20094-fold from the modal MIC of the EQA isolate.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The overall prevalence of AMR reported by Euro-GASP reflects closely the AMR situation for <jats:italic>N. gonorrhoeae<\/jats:italic> in the EU\/EEA. Euro-GASP data can be used to provide robust AMR estimates to inform the European guideline for the management of gonorrhoea.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12879-019-4631-x","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T11:04:07Z","timestamp":1575975847000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["The European gonococcal antimicrobial surveillance programme (Euro-GASP) appropriately reflects the antimicrobial resistance situation for Neisseria gonorrhoeae in the European Union\/European Economic Area"],"prefix":"10.1186","volume":"19","author":[{"name":"The Euro-GASP network","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6707-6910","authenticated-orcid":false,"given":"Michelle J.","family":"Cole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Quinten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Jacobsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Amato-Gauci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Woodford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Spiteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Unemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"4631_CR1","unstructured":"Tapsall J. Antimicrobial resistance in Neisseria gonorrhoeae. World Health Organisation 2001. http:\/\/whqlibdoc.who.int\/hq\/2001\/WHO_CDS_CSR_DRS_2001.3.pdf. Accessed 3 Dec 2019."},{"key":"4631_CR2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/jac\/dkl265","volume":"58","author":"IM Martin","year":"2006","unstructured":"Martin IM, Hoffmann S, Ison CA. European surveillance of sexually transmitted infections (ESSTI): the first combined antimicrobial susceptibility data for Neisseria gonorrhoeae in Western Europe. J Antimicrob Chemother. 2006;58:587\u201393.","journal-title":"J Antimicrob Chemother"},{"key":"4631_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1258\/ijsa.2009.009160","volume":"20","author":"C Bignell","year":"2009","unstructured":"Bignell C. 2009 European (IUSTI\/WHO) guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2009;20:453\u20137.","journal-title":"Int J STD AIDS"},{"key":"4631_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/0956462412472837","volume":"24","author":"C Bignell","year":"2013","unstructured":"Bignell C, Unemo M. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2013;24:85\u201392.","journal-title":"Int J STD AIDS"},{"key":"4631_CR5","unstructured":"European Centre for Disease Prevention and Control. Gonococcal antimicrobial susceptibility surveillance in Europe 2009. 2011. https:\/\/ecdc.europa.eu\/sites\/portal\/files\/media\/en\/publications\/Publications\/1101_SUR_Gonococcal_susceptibility_2009.pdf. Accessed 3 Dec 2019."},{"key":"4631_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1186\/s12879-017-2707-z","volume":"17","author":"MJ Cole","year":"2017","unstructured":"Cole MJ, Spiteri G, Jacobsson S, Woodford N, Tripodo F, Amato-Gauci AJ, et al. Overall low extended-spectrum cephalosporin resistance but high azithromycin resistance in Neisseria gonorrhoeae in 24 European countries, 2015. BMC Infect Dis. 2017;17:617.","journal-title":"BMC Infect Dis"},{"key":"4631_CR7","unstructured":"European Centre for Disease Prevention and Control. Gonococcal antimicrobial susceptibility surveillance in Europe 2014. 2016. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/media\/en\/publications\/Publications\/gonococcal-antimicrobial-susceptibility-surveillance-Europe-2014.pdf. Accessed 3 Dec 2019."},{"key":"4631_CR8","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/OLQ.0000000000000185","volume":"41","author":"MJ Cole","year":"2014","unstructured":"Cole MJ, Spiteri G, Town K, Unemo M, Hoffmann S, Chisholm SA, et al. Risk factors for antimicrobial-resistant Neisseria gonorrhoeae in Europe. Sex Transm Dis. 2014;41:723\u20139.","journal-title":"Sex Transm Dis"},{"key":"4631_CR9","unstructured":"European Centre for Disease Prevention and Control. Annual Epidemiological Report 2016 \u2013 Gonorrhoea. 2016. https:\/\/ecdc.europa.eu\/sites\/portal\/files\/documents\/Gonorrhoea%20AER_0.pdf. Accessed 3 Dec 2019."},{"key":"4631_CR10","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/sextrans-2011-050071","volume":"87","author":"G Hughes","year":"2011","unstructured":"Hughes G, Nichols T, Ison CA. Estimating the prevalence of gonococcal resistance to antimicrobials in England and Wales. Sex Transm Infect. 2011;87:526\u201331.","journal-title":"Sex Transm Infect"},{"key":"4631_CR11","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.1. 2018. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_8.1_Breakpoint_Tables.pdf. Accessed 3 Dec 2019."},{"key":"4631_CR12","unstructured":"European Centre for Disease Prevention and Control. Annual epidemiological report: Sexually transmitted infections, including HIV and blood-borne viruses 2014. 2016. https:\/\/ecdc.europa.eu\/sites\/portal\/files\/media\/en\/publications\/Publications\/sexually-transmited-infections-HIV-AIDS-blood-borne-annual-epi-report-2014.pdf. Accessed 3 Dec 2019."},{"key":"4631_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/1471-2334-14-433","volume":"14","author":"A Brunner","year":"2014","unstructured":"Brunner A, Nemes-Nikodem E, Mihalik N, Marschalko M, Karpati S, Ostorhazi E. Incidence and antimicrobial susceptibility of Neisseria gonorrhoeae isolates from patients attending the national Neisseria gonorrhoeae reference laboratory of Hungary. BMC Infect Dis. 2014;14:433.","journal-title":"BMC Infect Dis"},{"key":"4631_CR14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/jac\/22.4.463","volume":"22","author":"N Woodford","year":"1988","unstructured":"Woodford N, Ison CA. The effect of media on antimicrobial susceptibility testing of Neisseria gonorrhoeae. J Antimicrob Chemother. 1988;22:463\u201371.","journal-title":"J Antimicrob Chemother"},{"key":"4631_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1017\/S0950268800030508","volume":"103","author":"KM Bindayna","year":"1989","unstructured":"Bindayna KM, Ison CA. Sampling methods for monitoring changes in gonococcal populations. Epidemiol Infect. 1989;103:203\u20139.","journal-title":"Epidemiol Infect"},{"key":"4631_CR16","first-page":"143","volume":"29","author":"G Samaan","year":"2005","unstructured":"Samaan G, Roche PW, Greig JE, Tapsall JW. Australian Gonococcal surveillance Programme. Evaluation of the Australian Gonococcal surveillance Programme. Commun Dis Intell Q Rep. 2005;29:143\u20139.","journal-title":"Commun Dis Intell Q Rep"},{"key":"4631_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1136\/sextrans-2014-051756","volume":"91","author":"H Mohammed","year":"2015","unstructured":"Mohammed H, Ison CA, Obi C, Chisholm S, Cole M, Quaye N, et al. Frequency and correlates of culture-positive infection with Neisseria gonorrhoeae in England: a review of sentinel surveillance data. Sex Transm Infect. 2015;91:287\u201393.","journal-title":"Sex Transm Infect"},{"key":"4631_CR18","unstructured":"European Centre for Disease Prevention and Control. Gonococcal antimicrobial susceptibility surveillance in Europe 2015. 2017. https:\/\/ecdc.europa.eu\/sites\/portal\/files\/documents\/gonococcal-antimicrobial-susceptibility-surveillance-Europe-2015.pdf. Accessed 3 Dec 2019."},{"key":"4631_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6507a1","volume":"65","author":"RD Kirkcaldy","year":"2016","unstructured":"Kirkcaldy RD, Harvey A, Papp JR, Del Rio C, Soge OO, Holmes KK, et al. Neisseria gonorrhoeae antimicrobial susceptibility surveillance - the Gonococcal isolate surveillance project, 27 sites, United States, 2014. MMWR Surveill Summ. 2016;65:1\u201319.","journal-title":"MMWR Surveill Summ"},{"key":"4631_CR20","unstructured":"European Centre for Disease Prevention and Control. Euro-GASP 2016 external quality assessment (EQA) scheme for Neisseria gonorrhoeae antimicrobial susceptibility testing 2017. https:\/\/ecdc.europa.eu\/sites\/portal\/files\/documents\/EQA%20Report%202016%20final.pdf. Accessed 3 Dec 2019."},{"key":"4631_CR21","doi-asserted-by":"publisher","first-page":"5220","DOI":"10.1128\/AAC.00786-15","volume":"59","author":"M Unemo","year":"2015","unstructured":"Unemo M, Ringlander J, Wiggins C, Fredlund H, Jacobsson S, Cole M. High in vitro susceptibility to the novel Spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014. Antimicrob Agents Chemother. 2015;59:5220\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"4631_CR22","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1093\/jac\/dkw279","volume":"71","author":"S Jacobsson","year":"2016","unstructured":"Jacobsson S, Golparian D, Cole M, Spiteri G, Martin I, Bergheim T, et al. WGS analysis and molecular resistance mechanisms of azithromycin-resistant (MIC >2 mg\/L) Neisseria gonorrhoeae isolates in Europe from 2009 to 2014. J Antimicrob Chemother. 2016;71:3109\u201316.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"4631_CR23","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1473-3099(18)30225-1","volume":"18","author":"SR Harris","year":"2018","unstructured":"Harris SR, Cole MJ, Spiteri G, Sanchez-Buso L, Golparian D, Jacobsson S, et al. Public health surveillance of multidrug-resistant clones of Neisseria gonorrhoeae in Europe: a genomic survey. Lancet Infect Dis. 2018;18(7):758\u201368.","journal-title":"Lancet Infect Dis"},{"key":"4631_CR24","doi-asserted-by":"publisher","first-page":"e1002344","DOI":"10.1371\/journal.pmed.1002344","volume":"14","author":"T Wi","year":"2017","unstructured":"Wi T, Lahra MM, Ndowa F, Bala M, Dillon JR, Ramon-Pardo P, et al. Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action. PLoS Med. 2017;14:e1002344.","journal-title":"PLoS Med"},{"key":"4631_CR25","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1097\/OLQ.0b013e318232459b","volume":"38","author":"JA Dillon","year":"2011","unstructured":"Dillon JA. Sustainable antimicrobial surveillance programs essential for controlling Neisseria gonorrhoeae superbug. Sex Transm Dis. 2011;38:899\u2013901.","journal-title":"Sex Transm Dis"},{"key":"4631_CR26","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1093\/jac\/dkw288","volume":"71","author":"M Unemo","year":"2016","unstructured":"Unemo M, Golparian D, Sanchez-Buso L, Grad Y, Jacobsson S, Ohnishi M, et al. The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization. J Antimicrob Chemother. 2016;71:3096\u2013108.","journal-title":"J Antimicrob Chemother"},{"key":"4631_CR27","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1080\/14737159.2017.1360137","volume":"17","author":"V Dona","year":"2017","unstructured":"Dona V, Low N, Golparian D, Unemo M. Recent advances in the development and use of molecular tests to predict antimicrobial resistance in Neisseria gonorrhoeae. Expert Rev Mol Diagn. 2017;17:845\u201359.","journal-title":"Expert Rev Mol Diagn"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4631-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4631-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4631-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T01:02:29Z","timestamp":1607475749000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4631-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4631"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4631-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"23 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All examined gonococcal isolates were cultured and preserved as part of the routine diagnostics (standard care), and isolates or data were submitted to the Euro-GASP surveillance study with no patient identification information. Ethical approval was not required; ECDC has a legal basis to collect surveillance data (DECISION No 1082\/2013\/EU).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. However, PHE\u2019s AMRHAI Reference Unit has received financial support for conference attendance, lectures, research projects or contracted evaluations from numerous sources, including: Accelerate Diagnostics, Achaogen Inc., Allecra Therapeutics, Amplex, AstraZeneca UK Ltd., AusDiagnostics, Basilea Pharmaceutica, Becton Dickinson Diagnostics, bioM\u00e9rieux, Bio-Rad Laboratories, BSAC, Cepheid, Check-Points B.V., Cubist Pharmaceuticals, Department of Health, Enigma Diagnostics, Food Standards Agency, GlaxoSmithKline Services Ltd., Helperby Therapeutics, Henry Stewart Talks, IHMA Ltd., Innovate UK, Kalidex Pharmaceuticals, Melinta Therapeutics, Merck Sharpe & Dohme Corp., Meiji Seika Pharma Co. Ltd., Mobidiag, Momentum Biosciences Ltd., Neem Biotech, Nordic Pharma Ltd., Norgine Pharmaceuticals, Rempex Pharmaceuticals Ltd., Roche, Rokitan Ltd., Smith & Nephew UK Ltd., Shionogi & Co. Ltd., Trius Therapeutics, VenatoRx Pharmaceuticals and Wockhardt Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1040"}}